Compare AbCellera Biologics Inc (ABCL) vs Clorox Co (CLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Clorox Co — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Clorox Co trades at $94.94 (market cap $11.78B). The key difference: Clorox Co is far larger — about 5× AbCellera Biologics Inc's market cap, and Clorox Co pays a 5.09% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CLX | |
|---|---|---|
Market Cap | $2.35B | $11.78B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $131.43 |
52-Week Low | $2.78 | $86.12 |
Enterprise Value | $1.99B | $15.08B |
Dividend Yield | — | 5.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CLX trades at $97.41, up 0.15% on the day, with a neutral technical signal and key support at $96. The company reported Q1 2026 EPS of $1.64, beating expectations, and maintains strong profitability with an 11.18% net margin. Recent news highlights a simplified operating structure and CEO transition, while analyst consensus is a $103.38 price target with a hold-heavy rating distribution.
The outlook is mixed: solid fundamentals and a nearly 5% dividend yield support income investors, but high debt levels and competitive pressures pose risks. Upside depends on execution of new growth initiatives under incoming leadership, with current valuation appearing reasonable relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
